Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo
Vertex Pharmaceuticals’s non-opioid-based pain therapy has shown benefit in a Phase II trial in patients with painful lumbosacral radiculopathy (LSR)…
Latest News
-
-
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
AC Immune’s stock price has jumped by more than 20% after all patients in a trial of its Parkinson’s disease…
-
ARIA-E risk of Lilly’s Kisunla in Alzheimer’s reduced with modified dosing
A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related imaging abnormalities with…
-
ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific
Immatics has been left with the full rights to develop a bispecific molecule after its partner Bristol Myers Squibb (BMS)…
-
Moderna mpox mRNA vaccine shows early promise in monkey study
Moderna has announced its mRNA vaccine in development for mpox is more effective than Bavarian Nordics Jynneos in prevention of…
-
Lykos cuts team by 75%, vows to keep MDMA program despite FDA veto
Lykos Therapeutics said it remains dedicated to continuing development of its midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD) after…
-
FDA drug application costs set to rise to $4.3m from October
The US Food and Drug Administration (FDA) has announced the cost to file a drug using clinical data will jump…
-
Standing ovation for Gilead as it boasts perfect efficacy in HIV PReP trial
Gilead received a standing ovation after announcing its full, perfect efficacy data from the Phase III PURPOSE 1 trial of…
-
UNAIDS boss calls on Gilead to provide ‘miracle’ drug to developing countries
The UNAIDS executive director has called upon Gilead Sciences to make its ‘miracle’ drug lenacapavir for human immunodeficiency virus (HIV)…
-
Seventh patient ‘cured’ of HIV among highlights at AIDS 2024
Researchers will present data from a ‘first-of-its-kind HIV cure’ stem cell transplant at the upcoming AIDS 2024 Conference. Experts will…
